NLRP3 and metabolic dysfunction-associated steatotic liver disease: Geniposide has been shown to inhibit NLRP3 inflammatory vesicle activation both in vivo and ex vivo (Yu et al., 2015) and reduce ATP- and hydrogen peroxide (H2O2)-mediated secretion of IL-1β (Rajanbabu et al., 2015), suggesting its potential as a therapeutic agent for NAFLD.